Universal-Beteiligungs- und Servicegesellschaft
PVLA

Universal-Beteiligungs- und Servicegesellschaft’s Palvella Therapeutics PVLA Stock Holding History

Universal-Beteiligungs- und Servicegesellschaft’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$442K Buy
+3,544
New +$370K ﹤0.01% 1760

Other funds holding PVLA

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft's PVLA Position: Q1 2026 in Review

Universal-Beteiligungs- und Servicegesellschaft opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 3,544 shares worth $442K. The stake represents ﹤0.01% of the portfolio and ranks #1760 among its holdings.

180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

  • Universal-Beteiligungs- und Servicegesellschaft held 3,544 shares of Palvella Therapeutics worth $442K as of Q1 2026.
  • Palvella Therapeutics was a new Universal-Beteiligungs- und Servicegesellschaft position in Q1 2026.
  • Palvella Therapeutics made up ﹤0.01% of Universal-Beteiligungs- und Servicegesellschaft's portfolio in Q1 2026, its #1760 holding.
  • 180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on Universal-Beteiligungs- und Servicegesellschaft's 13F filing for Q1 2026, filed 11 May 2026.